Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

2020 Bulkers Ltd. (2020) - Conversion of index-linked charter hire for Bulk Shenzhen and Bulk Sydney

Hamilton, Bermuda, September 29, 2021 2020 Bulkers has today converted the index-linked charters for Bulk Shenzhen and Bulk Sydney into fixed rate charters at US$61,628 and US$60,260 per ship per day, gross, for the period from November 1, 2021 until December 31, 2021. In addition, both vessels will still earn a premium related to the fuel cost savings from the scrubbers. The Company expects average operating cash breakeven after G&A, vessel operating costs and debt service of approximately US$14,500 per ship per day for 2021.   For further queries, please contact:  Magnus

NENT Group adapts ‘Karma and Jonar’ as animated kids Viaplay Original

· ‘Karma and Jonar’ uses Viaplay Studios’ state-of-the-art 3D animation technology · Eight-part series is based on bestselling children’s books by an anonymous author · NENT Group to premiere at least 50 Viaplay Originals in 2021 Nordic Entertainment Group (NENT Group), one of the world’s fastest growing streaming companies, will adapt the bestselling ‘Karma and Jonar’ children’s books as its latest Viaplay Original for younger viewers. The eight-part animated series uses Viaplay Studios’ state-of-the-art 3D animation technology and is the first Viaplay Studios production following

Initiation of clinical imaging study

Annexin Pharmaceuticals and Collaborators Initiate a Clinical Study in Patients with Retinal Vein Occlusion (RVO) Using Fluorescent Labelled ANXV.STOCKHOLM, SWEDEN (September 29, 2021) – Annexin Pharmaceuticals AB (publ) (“Annexin”) announces that its collaborators have received approval from the Dutch regulatory authority to start an innovative clinical molecular imaging study of Annexin’s fluorescent labelled candidate drug ANXV in patients with venous occlusion in the retina (RVO). The trial is managed by TRACER, a CRO specialized in fast-track clinical imaging trials, and is being

Invitation to Axfood's Capital Markets Day 2021

Axfood invites analysts, investors and the press to a Capital Markets Day to be held on 16 December 2021.The Capital Markets Day will be held at Axfood’s Head Office, Solnavägen 4 in Stockholm. Lunch will be served from 12.00 p.m. (CET). The event will start at 1.00 p.m. (CET) and is estimated to end at 4.30 p.m. (CET), followed by a mingle. The purpose with the Capital Markets Day is to provide an update of Axfood’s long term strategy and financial targets. Focus will be on the development for the Group’s various businesses and strategic initiatives within areas such as logistics and

Hufvudstaden to launch framework for green bonds

Hufvudstaden is to launch a framework for green bonds and increase the established MTN programme to SEK 12 billion for borrowing in the Swedish bond market. The aim of the framework is to finance green properties and invest in projects promoting climate transition and sustainability. The framework has undergone an independent evaluation by Cicero (Cicero Shades of Green), which issued a second opinion with the grade of “Medium Green” in terms of the level of greenness and a score of “Excellent” for governance. “The green framework is a natural part of Hufvudstaden’s sustainability

TCO Certified quiz reveals what we know about e-waste

“Talking about e-waste is really important to help buyers take a more holistic approach to their electronic goods”, says Gabriella Mellstrand, Marketing and Communication Director at TCO Development.October 14th is International E-waste Day, an initiative aimed at reducing the burden that e-waste places on the environment and saving natural resources. To support educational and public awareness activities linked to the initiative, TCO Development  launched an e-waste quiz. TCO Development is the organization behind TCO Certified, the world’s most comprehensive

Neste announces groundbreaking global partnership with TripActions and Reed & Mackay to provide SAF to TripActions Group customers

Neste Corporation, Press Release, 29 September 2021 at 10 a.m. (EET)TripActions and Reed & Mackay, the fastest-growing travel and spend management group and Neste, the world’s leading sustainable aviation fuel producer, today announced a groundbreaking global partnership to offer Neste MY Sustainable Aviation Fuel™  to all TripActions Group customers. The agreement marks the first time that a corporate travel management company is able to provide customers with the option to buy sustainable aviation

Spicy packaging wins the design competition PIDA

The BillerudKorsnäs prestigious design competition PIDA has been completed. The overall winner is the French entry “RESPICE” made by the three design students Romane Bazile, Jeanne Douchet and Marion Braconnier from IUT Reims. The winning concept challenges conventional packaging and awakens the senses.The winning students describe their packaging project as follows:“RESPICE is a way to spice up your life. It is a really tasty box to put in your kitchen as a decorative display. The opening of the box provokes a sound that excites your hearing and allows you to guess at the ingredients.

Linxon advances floating substation technology

Floating substations will enable the next phase of the booming offshore wind power industry. Achieving an efficient and reliable floating substation is key to decarbonizing the electricity grid by unlocking large offshore wind generation potential.The installed capacity of floating offshore wind generation is forecast to grow from a modest 66 MW in 2019 to at least 16 GW in 2030[1], as more and more countries in Europe, Asia and North America seek to harness the rich potential of deep-water wind resources.   The wind industry is eager to develop and adopt commercial-scale floating

New version of Bittium Cardiac Navigator™ Analysis Software Detects AV Blocks and Speeds up the Analysis of Long-Term ECG Measurements

Press release Free for publication on September 29, 2021, at 10.00 a.m. (CEST +1) New version of Bittium Cardiac Navigator™ Analysis Software Detects AV Blocks and Speeds up the Analysis of Long-Term ECG Measurements Oulu, Finland, September 29, 2021 – Bittium, a leading specialist for secure communications, connectivity, and medical technology solutions, releases a new version of Bittium Cardiac Navigator™ Holter ECG Analysis Software. The new Bittium Cardiac Navigator™ 1.5. Software version introduces the detection of atrioventricular blocks (AV blocks). The application now

BioStock: Sprint Bioscience initiates marketing of the DISA-program

The preclinical development experts at Sprint Bioscience started the second half of the year by signing the company’s largest licensing agreement to date in a deal concerning drug candidate Vps34. The company is now initiating marketing for the next project in line. BioStock spoke to the company’s Chief Scientific Officer, Martin Andersson, to find out more about the project.Read the full article at biostock.se:https://www.biostock.se/en/2021/09/sprint-bioscience-initiates-marketing-of-the-disa-program/This is a press release from BioStock - Connecting Innovation & Capital. https://www.

Transactions in connection with share buy-back programme

On 4 March 2021, H+H International A/S (hereinafter referred to as “H+H” or “the Company”) initiated a share buy-back programme in compliance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on Market Abuse and Commission Delegated Regulation (EU) 1052/2016 of 8 March 2016 (the “Safe Harbour Regulation”). On 18 March 2021, the share buy-back programme was increased by DKK 15 million, thereby increasing the maximum aggregate purchase price of the shares to be bought back under the programme to DKK 115 million. The share buy-back

Casking raises the bar for gym hygiene

Biomaster partner Casking has developed a range of gym grips with inbuilt antimicrobial technology. Suitable for barbells from 28mm - 30mm diameter, the grips cover the length of a barbell, inhibiting the growth of bacteria on the grip surface. The product can be manufactured in a range of colours and is installed using a special applicator tool. The reality of sharing gym equipment with potentially thousands of other people is that you are likely to come into contact with unwanted microbes along the way. You may be a conscientious sanitiser and always wipe down your gear before

Hanna Hoikkala appointed Press Officer at SSAB

Hanna Hoikkala has been appointed Press Officer and communications expert at SSAB.Hanna Hoikkala has a decade of journalism experience, and joins SSAB from news agency Bloomberg News, where she was a reporter covering parts of Nordic finance. Hoikkala´s background also extends to studies in biology and economics, among other topics. “I´m really happy to join SSAB, and excited to be part of the sustainability journey that it has undertaken,” Hanna Hoikkala says. “Becoming more sustainable is a challenge we all face, and it´s really great to be able to join a company with such a clear

Metso Outotec includes sustainability targets and extends the maturity of its Revolving Credit Facility

Metso Outotec Corporation’s stock exchange release on September 29, 2021, at 09:40 a.m. EESTMetso Outotec has agreed with its banking group to include sustainability targets to its EUR 600 million Syndicated Revolving Credit Facility, as well as to utilize the facility’s remaining one-year extension option. The sustainability targets included in the facility are: · CO\2 \emissions from the Group’s own operations · CO\2\ emissions from the Group’s logistics · The Group’s suppliers having a Science Based CO\2\ emissions target The development of these targets will be measured

BioStock: Fluicell partners with big pharma for 3-D bioprinting project

Single-cell technology developers Fluicell have a good reputation in the biomedical research field for its cutting-edge products aimed at maximising R&D capabilities. Fluicell’s 3-D bioprinter Biopixlar has been the main driver for growth thanks to its increased popularity in the industry, and the company announced last week that it has partnered with a big pharma player to use Biopixlar to create bioprinted heart tissue for safety pharmacological studies.Read the full article at biostock.se: https://www.biostock.se/en/2021/09/fluicell-partners-with-big-pharma-for-3-d-bioprinting-project/

Annual Spine Technology Awards confirm Sectra as a frontrunner in orthopaedics

Linköping, Sweden – September 29, 2021 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B), together with its clinical collaboration partners, has been acknowledged for its implant movement analysis service, Sectra IMA. Sectra was recognized by RRY Publications LLC and Orthopedics This Week for its innovative technology developed to improve the standard of care for patients with spine disease. The award will be handed out at the 36th Annual Meeting of the North American Spine Society (NASS) in Boston, USA.Sectra Implant Movement Analysis (

Brazil grants patent for VAL001

The Brazilian National Institute of Industrial Property (INPI) has announced the intent to grant Respiratorius patent for VAL001.After the formal fees have been paid, the patent will be granted, which will give Respiratorius market exclusivity in Brazil until 2031. Previously, the patent has been granted in Europe, US, Japan, Canada, and Korea under equivalent conditions. The patent covers a combination of an HDAC inhibitor and a steroid for pre-treatment with standard chemotherapy (R-CHOP) in the treatment of diffuse large B-cell lymphoma (DLBCL), a lymphoma which annually affects about

Rejlers creates the office of the future in Gårda Vesta – Gothenburg's new landmark

Rejlers in Gothenburg has moved into a new modern office space in Gårda Vesta. Platzer's new office high-rise Gårda Vesta in Gothenburg is a new landmark in the city and the first WELL-certified building where great focus has been placed on well-being and health in the workplace. On floor 21-23, Rejlers has shaped the smart office of the future, where creative meeting places and new technical solutions contribute to increased flexibility, productivity and security.Since the pandemic, the offices and the image of our workplaces have changed. The trend is towards increased flexibility where

IRRAS’ IRRAflow[®] System Demonstrates Ability to Treat Pyogenic Ventriculitis through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open

· Neurosurgeons from Helsinki University Hospital successfully treated two patients with aggressive brain infections by irrigating an antibiotic solution directly in the brain’s ventricles using IRRAflow’s fluid exchange capabilities. · Aggressive ventriculitis traditionally results in mortality approximately 60% of the time with 80% of patients experiencing long-term adverse outcomes. · Treatment with IRRAflow allowed the antibiotic to reach therapeutic levels within the brain’s cerebrospinal fluid without negatively impacting the brain tissue.Stockholm, September 29, 2021 - IRRAS, a

Mandatory notification of trade

Anooj Unarket, Board member of Otello Corporation ASA, has on behalf of certain related parties, as of 28th September 2021, acquired interests in shares of Otello Corporation ASA. The balance of Anooj Unarket and related parties’ holdings after the transaction totals 25,872,512 shares. Please refer to the attached notification of trading for further details. This information is subject to disclosure requirements in regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

XNK Therapeutics targets broader pipeline opportunities for its NK cell therapy

September 29, 2021 XNK Therapeutics AB (“XNK”) today announced plans to further expand the scope of its proprietary technology platform of natural killer (NK) cell therapies outside of multiple myeloma to also include other cancer indications to broaden the pipeline. The company will begin the preclinical and commercial work to expand the pipeline and expects to announce a decision in Q1 2022.XNK is at the forefront of the clinical development and manufacturing of autologous natural killer cell-based products by using its proprietary technology platform. XNK has promising clinical data

Senior management change at Concentric AB

David Bessant has decided to leave his position as Senior Vice President of Europe and Rest of the World.  His last day with the Company will be 29 September 2021, when John Beadsworth, formerly the Managing Director of Concentric Birmingham & Pune, will assume his position on an interim basis. The work to recruit a permanent successor is underway. David Bessant commented: “My journey with Concentric has been enjoyable and I would like to thank the team for all their support over the last 12 years.” David Woolley, CEO of Concentric, commented: “Ever since joining Concentric in 2009,

AstraZeneca to fully acquire Caelum Biosciences

29 September 2021 07:00 BST AstraZeneca to fully acquire Caelum Biosciences AstraZeneca will advance and accelerate ongoing Phase III clinical development ofCAEL-101, a potential first-in-class medicine for AL amyloidosis AstraZeneca's Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences for CAEL-101, a potentially first-in-class fibril-reactive monoclonal antibody (mAb) for the treatment of light chain (AL) amyloidosis. AL amyloidosis is a rare disease in which misfolded amyloid proteins build up in organs throughout the body, including the

There are no items matching the current filter
There are no more items matching the current filter
Back to top